Loading...
•
Dec 31, 2025
Rapport Therapeutics Inc Q4 2025 Earnings Report
Rapport Therapeutics reported increased R&D spending and a wider quarterly loss as it advanced its neuroscience pipeline while maintaining a strong cash position.
Key Takeaways
Rapport Therapeutics reported a Q4 2025 net loss as operating expenses increased due to expanding clinical development activities. The company continued advancing RAP-219 and other pipeline programs while maintaining a strong balance sheet to support operations into 2029.
Net loss for Q4 2025 was $33763000 compared to $19980000 in Q4 2024.
Research and development expenses rose to $30258000 driven by clinical development activities.
General and administrative expenses increased to $8251000 as the business scaled.
Cash, cash equivalents and short-term investments totaled $490539000 at quarter end.
Forward Guidance
Rapport expects to advance RAP-219 across multiple neurological indications with several clinical milestones ahead while maintaining funding through the second half of 2029.
Positive Outlook
- Phase 3 program for RAP-219 in focal onset seizures expected to begin in Q2 2026.
- Expansion of RAP-219 program into primary generalized tonic-clonic seizures.
- Strategic collaboration with Tenacia to develop RAP-219 in Greater China.
- Strong balance sheet expected to fund operations into the second half of 2029.
- Additional pipeline progress including bipolar mania Phase 2 trial.
Challenges Ahead
- Company continues to report significant operating losses.
- Pipeline assets remain in clinical development with regulatory uncertainty.
- R&D spending increased significantly year over year.
- Commercial revenue has not yet been established.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...